Argos Therapeutics signed an exclusive licensing agreement with Therakos, a Johnson & Johnson company, for the research and development of new treatments based on Argos’ regulatory T-cell technology.
Argos is actively developing immunotherapies or indications such as cancer, infectious diseases, autoimmune disorders, and transplantation using its Arcelis technology, which trains the immune system to recognize and attack the disease.
“The licensing agreement with Therakos will enable accelerated development of an asset outside our primary focus, while providing Argos with nondilutive financial resources,” said John Bonfiglio, Ph.D., president and CEO at Argos Therapeutics. “This transaction further demonstrates our ability to leverage Argos´ leading immunotherapy science both through our own programs as well as through collaborations with select corporate partners."